Dennis Cho Sells 531 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) insider Dennis Cho sold 531 shares of the business's stock in a transaction dated Wednesday, May 21st. The shares were sold at an average price of $29.75, for a total value of $15,797.25. Following the completion of the transaction, the insider now owns 105,318 shares in the company, valued at $3,133,210.50. This trade represents a 0.50% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Dennis Cho also recently made the following trade(s):

• On Monday, May 5th, Dennis Cho sold 689 shares of Twist Bioscience stock. The stock was sold at an average price of $37.65, for a total value of $25,940.85.
• On Wednesday, April 2nd, Dennis Cho sold 124 shares of Twist Bioscience stock. The stock was sold at an average price of $38.73, for a total transaction of $4,802.52.
• On Thursday, March 20th, Dennis Cho sold 230 shares of Twist Bioscience stock. The shares were sold at an average price of $41.68, for a total value of $9,586.40.
• On Friday, March 14th, Dennis Cho sold 92 shares of Twist Bioscience stock. The stock was sold at an average price of $40.05, for a total transaction of $3,684.60.
• On Thursday, March 6th, Dennis Cho sold 277 shares of Twist Bioscience stock. The shares were sold at an average price of $40.91, for a total transaction of $11,332.07.

Twist Bioscience Stock Performance

TWST traded down $1.08 during trading on Wednesday, reaching $28.33. 1,142,745 shares of the company's stock were exchanged, compared to its average volume of 978,754. The company has a market capitalization of $1.70 billion, a P/E ratio of -8.38 and a beta of 2.54. The business has a 50 day moving average price of $35.90 and a 200 day moving average price of $42.50. Twist Bioscience Co. has a fifty-two week low of $27.12 and a fifty-two week high of $60.90. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.10). Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The firm had revenue of $92.79 million for the quarter, compared to analyst estimates of $92.00 million. As a group, analysts predict that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Twist Bioscience by 186.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,442,262 shares of the company's stock worth $95,883,000 after acquiring an additional 1,588,587 shares in the last quarter. First Light Asset Management LLC bought a new position in Twist Bioscience in the fourth quarter valued at approximately $56,984,000. EdgePoint Investment Group Inc. bought a new stake in Twist Bioscience during the first quarter worth $43,705,000. Marshall Wace LLP lifted its stake in Twist Bioscience by 15,927.8% in the 4th quarter. Marshall Wace LLP now owns 846,107 shares of the company's stock valued at $39,319,000 after purchasing an additional 840,828 shares during the last quarter. Finally, Nuveen LLC bought a new position in shares of Twist Bioscience during the 1st quarter worth approximately $31,960,000.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on TWST shares. Scotiabank reaffirmed an "outperform" rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. The Goldman Sachs Group reduced their price target on shares of Twist Bioscience from $55.00 to $48.00 and set a "buy" rating on the stock in a research report on Tuesday, May 6th. Robert W. Baird cut their target price on Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 6th. Barclays decreased their target price on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating for the company in a research report on Thursday, April 10th. Finally, Guggenheim reissued a "buy" rating and set a $50.00 price target on shares of Twist Bioscience in a report on Tuesday, May 6th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $50.40.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.